Overview

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

Status:
NOT_YET_RECRUITING
Trial end date:
2028-11-04
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect and safety of 626 in patients with SLE
Phase:
PHASE1
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.